Table S2. Crude and directly age- and sex-standardized prevalence (%) of metabolic syndrome components by year

Year	AO crude	AO ASR	HBP crude	HBP ASR	HG crude	HG ASR	HTG crude	HTG ASR	Low HDL crude	Low HDL ASR
2014	21.0	21.1	42.3	42.9	34.7	35.0	30.0	29.7	22.5	23.0
2015	22.4	22.5	42.8	43.2	35.9	36.0	30.3	30.0	22.1	22.4
2016	23.2	23.1	43.0	43.0	37.0	36.9	31.1	30.8	22.3	22.4
2017	23.9	23.7	43.6	43.3	38.3	38.0	32.2	31.8	22.1	22.0
2018	—	—	—	—	—	—	—	—	—	—
2019	24.8	24.9	43.6	43.7	39.8	39.9	—	—	—	—
2020	25.8	25.9	44.8	44.7	41.6	41.7	—	—	—	—
2021	25.7	25.9	44.6	44.8	41.6	41.8	—	—	—	—
2022	25.7	25.8	45.4	45.2	40.5	40.5	—	—	—	—
2023	25.5	25.6	45.1	44.7	40.1	39.9	—	—	—	—

Standard population: pooled number of examinees by sex and 15 five-year age bands across the analyzed years (2014–2017 and 2019–2023).
— : not analyzed (2018 for all components; 2018–2023 for lipid indicators), because the denominators are not comparable (see Methods). AO, abdominal obesity; HBP, hypertension (high blood pressure); HG, hyperglycemia; HTG, hypertriglyceridemia; HDL, high-density lipoprotein; ASR, age- and sex-standardized rate.

Trend estimates for age- and sex-standardized prevalence, 2014–2023 (2018 excluded)

Component	2014 (%)	2023 (%)	Change (%*p*)	Linear B (95% CI)	R^2	B, 2014–2017	B, 2019–2023	*p*, slope change
Abdominal obesity	21.1	25.6	+4.4	+0.513 (+0.348 to +0.677)	0.89	+0.848	+0.124	0.014
Hypertension	42.9	44.7	+1.8	+0.260 (+0.173 to +0.346)	0.88	+0.102	+0.244	0.496
Hyperglycemia	35.0	39.9	+4.8	+0.683 (+0.358 to +1.007)	0.78	+0.964	-0.120	0.061

B, annual change in percentage points (%*p*). Segmented model as in Table 1. CI, confidence interval. Because the same individuals are screened repeatedly across years, the confidence intervals and p-values are descriptive and likely to be too narrow.